<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Dosing regimen for digoxin-specific antibody (Fab) fragments in patients with digoxin toxicity</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael D Levine, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ayrn D O'Connor, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michele M Burns, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Stolbach, MD, MPH, FAACT, FACMT, FACEP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Ganetsky, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 09, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Digoxin-specific antibody (Fab) fragments are the definitive treatment for patients with severe digitalis poisoning.</p><p>Prior to the advent of digoxin-specific antibodies, treatment for cardiac glycoside toxicity was largely supportive [<a href="#rid1">1</a>]. In 1976, antibody fragments were first used successfully to treat patients [<a href="#rid2">2</a>]. These antibodies are highly effective, safe, and widely used in clinical practice [<a href="#rid3">3</a>].</p><p>The dosing of Fab fragments based upon different clinical scenarios is discussed here. The indications for treatment with Fab fragments, the diagnosis and general management of digitalis poisoning, and the clinical use of digitalis are all reviewed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/319.html" rel="external">"Digitalis (cardiac glycoside) poisoning", section on 'Antidotal therapy with antibody (Fab) fragments'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/938.html" rel="external">"Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1051.html" rel="external">"Treatment with digoxin: Initial dosing, monitoring, and dose modification"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/121087.html" rel="external">"Secondary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Digoxin'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">WHAT ARE FAB FRAGMENTS?</span><span class="headingEndMark"> — </span>Fab fragments are purified preparations consisting of the Fab portion of IgG anti-digoxin antibodies derived from immunized sheep. These fragments bind free digoxin, thereby forming digoxin-immune fragment complexes. As the level of free digoxin in plasma falls, the resulting concentration gradient facilitates dissociation of digoxin from the sodium-potassium ATPase. Digoxin-immune fragment complexes are renally excreted. Because of the large size of both <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> and the digoxin-immune complex, neither is effectively cleared by hemodialysis.</p><p class="headingAnchor" id="H477197687"><span class="h1">KINETICS AND ADVERSE EFFECTS OF FAB FRAGMENTS</span><span class="headingEndMark"> — </span>Fab fragments are commercially available as DigiFab [<a href="#rid4">4</a>]. Each vial of DigiFab contains 40 mg of Fab fragments and binds approximately 0.5 mg of <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>. DigiFab has an elimination half-life of approximately 15 to 20 hours. However, the half-life may be up to 10 times longer with renal impairment. The volume of distribution for DigiFab is 0.3 L/kg.</p><p>Hypersensitivity reactions are the primary adverse effects of DigiFab. Although uncommon, patients with known allergies to sheep or sensitivity to papain or other papaya extracts used to cleave the antibody are at highest risk.</p><p>Use of DigiFab may result in complete reversal of cardiac glycoside effects, precipitating an acute congestive heart failure exacerbation or loss of rate control in patients with atrial fibrillation.</p><p class="headingAnchor" id="H3"><span class="h1">CALCULATING THE DOSE</span><span class="headingEndMark"> — </span>The dose of DigiFab is determined by different methods depending on the clinical scenario and information available. The indications for treatment with DigiFab are described separately. (See  <a class="medical medical_review" href="/d/html/319.html" rel="external">"Digitalis (cardiac glycoside) poisoning", section on 'Antidotal therapy with antibody (Fab) fragments'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Neither the digoxin level nor amount ingested is known</span><span class="headingEndMark"> — </span>Treatment in cases of severe toxicity when the amount of <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> ingested is unknown consists of empiric Fab fragment dosing. Our approach depends upon whether or not cardiac arrest appears imminent.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient with relative hemodynamic stability</strong> – Most patients with <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> poisoning are relatively stable, and arrest is not imminent. In such patients, we administer two vials of Fab fragments over 30 minutes [<a href="#rid5">5,6</a>]. If clinical response is inadequate (ie, a perfusing rhythm has not returned), then an additional one to two vials are administered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patient in cardiac arrest or cardiac arrest appears imminent</strong> – The traditional empiric dosing strategy of 10 vials of Fab fragments in adults or five vials in children administered by slow intravenous (IV) push is reasonable [<a href="#rid4">4</a>]. The initial dose can be repeated if there is inadequate clinical response (although at this time, it is reasonable to reconsider the diagnosis of <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> toxicity). When empiric dosing is required in very small children, concern for volume overload must be considered.</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Amount of digoxin ingested is known but concentration is unknown</span><span class="headingEndMark"> — </span>The number of Fab fragment vials to give the patient with an acute overdose, when only the amount ingested is known, is based upon the total body load (TBL):</p><p class="bulletIndent1"><span class="glyph">●</span>Step 1 – Calculate the TBL:</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent2"><span class="glyph">•</span>TBL for <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> = Dose (in mg) ingested x 0.8</p></div></div><p></p><p class="bulletIndent2">(The value 0.8 reflects the bioavailability of digoxin)</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1"><span class="glyph">●</span>Step 2 – Number of vials = TBL/0.5</p></div></div><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent2"><span class="glyph">•</span>(TBL/0.5 is identical to TBL x 2, which may be an easier calculation)</p></div></div><p></p><p>The number of vials should be rounded up to the nearest whole number. As an example, if the TBL is determined to be 3.125 mg, the number of vials is 3.125/0.5 = 6.25, which is rounded up to 7 vials.</p><p class="headingAnchor" id="H6"><span class="h2">Steady state digoxin concentration is known</span><span class="headingEndMark"> — </span>The number of Fab fragment vials needed for treatment (ie, full reversal of <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> effects) when the concentration is known is calculated based upon the drug concentration and the patient's weight:</p><div class="formulaContainer"><div class="formula"><p class="bulletIndent1"><span class="glyph">●</span>Number of vials = [(serum <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> concentration in ng/mL)(patient's weight in kg)]/100</p></div></div><p></p><p>The number of vials should be rounded up to the nearest whole number. As an example, if a patient has a <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> level of 4.4 ng/mL and weighs 65 kg, the number of vials would be (4.4 x 65)/100 = 2.86, which is rounded up to 3 vials. This formula provides an accurate and quick estimate of the antidote needed for treatment and is derived from a more complex pharmacokinetic calculation [<a href="#rid4">4</a>].</p><p>Partial reversal of <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> effects can be accomplished by providing half the calculated number of vials using the equation above. This approach is reasonable when concerned that full reversal may precipitate an acute congestive heart failure exacerbation or loss of rate control in atrial fibrillation (eg, patient with baseline reduced ejection fraction).</p><p>Note that the formula for calculating the number of Fab fragment vials needed based upon the serum concentration of <strong>digitoxin</strong> (which remains in use outside the United States) is <strong>not</strong> the same as that used for digoxin.</p><p class="headingAnchor" id="H7"><span class="h2">Cardiac glycoside poisoning other than digoxin or digitoxin</span><span class="headingEndMark"> — </span>Quantitative serum levels obtained in poisonings from cardiac glycosides other than digoxin or digitoxin do <strong>not</strong> correlate with measurements of these drugs and cannot be used to calculate the Fab fragment dose. Therefore, empiric treatment is provided as if neither the amount ingested nor the concentration was known (10 vials initially). These are starting doses; higher doses may be needed if clinical response is inadequate.</p><p class="headingAnchor" id="H8"><span class="h1">HOW TO ADMINISTER THE DRUG</span></p><p class="headingAnchor" id="H9"><span class="h2">Basic guidelines</span><span class="headingEndMark"> — </span>Fab fragments should be given over 30 minutes in all patients except those in cardiac arrest or in whom arrest is imminent. In such patients, the Fab fragments can be given as a slow intravenous (IV) push. It is important to emphasize that after Fab fragments are administered, total serum <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> concentrations will be unreliable; only free or unbound digoxin levels will be clinically useful.</p><p class="headingAnchor" id="H10"><span class="h2">Chronic toxicity without severe signs</span><span class="headingEndMark"> — </span>In individuals with chronic toxicity who do not manifest immediately life-threatening dysrhythmias (eg, atrioventricular [AV] nodal blockade present on electrocardiogram [ECG] but patient maintains normal blood pressure and clear mentation), half the recommended dose can be given initially in order to avoid unmasking the condition for which the patient is taking digoxin. Giving a full dose can elicit acute decompensated heart failure or atrial fibrillation with rapid ventricular response.</p><p class="headingAnchor" id="H3742969621"><span class="h1">ADDITIONAL RESOURCES</span></p><p class="headingAnchor" id="H2903248462"><span class="h2">Regional poison control centers</span><span class="headingEndMark"> — </span>Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/138307.html" rel="external">"Society guideline links: Regional poison control centers"</a>.)</p><p class="headingAnchor" id="H1615942384"><span class="h2">Society guideline links</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112689.html" rel="external">"Society guideline links: General measures for acute poisoning treatment"</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> – Digoxin-specific antibody (Fab) fragments consist of the Fab portion of IgG anti-digoxin antibodies. These fragments bind free digoxin, thereby forming digoxin-immune fragment complexes. As the level of free digoxin in plasma falls, the resulting concentration gradient facilitates dissociation of digoxin from the sodium-potassium ATPase. Fab fragment complexes are renally excreted. (See <a class="local">'What are Fab fragments?'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing regimens</strong> – The dosing of Fab fragments is based upon the clinical scenario, including whether the amount of digoxin ingested or the serum digoxin concentration is known. (See <a class="local">'Calculating the dose'</a> above and <a class="local">'How to administer the drug'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Known steady state <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> concentration (see <a class="local">'Steady state digoxin concentration is known'</a> above):</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent3"><span class="glyph">-</span>Full reversal of <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> effects: Number of vials (rounded up to whole number) = [(serum digoxin concentration in ng/mL)(patient's weight in kg)]/100</p></div></div><p></p><p class="bulletIndent3"><span class="glyph">-</span>Partial reversal of <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> effects: Half the number of vials calculated from the full reversal of digoxin effects formula above</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Neither <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> concentration nor amount ingested is known (see <a class="local">'Neither the digoxin level nor amount ingested is known'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients with relative hemodynamic stability, we administer two vials of Fab fragments, each over 30 minutes, and repeat based on clinical response.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients in cardiac arrest or if cardiac arrest appears imminent, we administer, by slow intravenous (IV) push, 10 vials of Fab fragments in adults or five vials in children. The initial dose can be repeated if there is inadequate clinical response.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ingested <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a> amount is known but concentration unknown: Number of vials (rounded up to whole number) = Dose (in mg) ingested x 1.6 (see <a class="local">'Amount of digoxin ingested is known but concentration is unknown'</a> above)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bayer MJ. Recognition and management of digitalis intoxication: implications for emergency medicine. Am J Emerg Med 1991; 9:29.</a></li><li><a class="nounderline abstract_t">Smith TW, Haber E, Yeatman L, Butler VP Jr. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med 1976; 294:797.</a></li><li><a class="nounderline abstract_t">Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation 1990; 81:1744.</a></li><li class="breakAll">DigiFab® US FDA approved product information. https://www.fda.gov/media/74693/download (Accessed on September 20, 2021).</li><li><a class="nounderline abstract_t">Chan BS, Isbister GK, Chiew A, et al. Clinical experience with titrating doses of digoxin antibodies in acute digoxin poisoning. (ATOM-6). Clin Toxicol (Phila) 2022; 60:433.</a></li><li><a class="nounderline abstract_t">Chan BS, Isbister GK, O'Leary M, et al. Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). Clin Toxicol (Phila) 2016; 54:488.</a></li></ol></div><div id="topicVersionRevision">Topic 328 Version 25.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1997019" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recognition and management of digitalis intoxication: implications for emergency medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/943040" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2188752" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2188752" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34424803" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Clinical experience with titrating doses of digoxin antibodies in acute digoxin poisoning. (ATOM-6).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27118413" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1).</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
